Advantages of intraperitoneal chemotherapy in treatment of ovarian cancer peritoneal carcinomatosis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The purpose of the study is to compare antitumor activity of different drugs at their Intraperitoneal (i. p.) and intravenous (i.v.) administration in rats with ovarian cancer peritoneal carcinomatosis. The study was carried out in 124 Wistar female rats with ovarian cancer which was inoculated i. p. After ovarian cancer inoculation rats were randomized in 12 groups, 10 rats in each group. There were six groups where saline (2 ml, i.p. control group) or the drugs (dioxadet 1.5 mg/kg, cisplatin 4mg/kg, mitomycin C 1.5 mg/kg, melphalan 2 mg/kg, paclitaxel 5 mg/kg) were administered i. p. In other six groups saline (2 ml, i. v. control group) and the named above drugs at the same doses were administered i. v. Antitumor effects of the treatment were estimated by increase in survival time (IST) comparing median survival time of rats in different groups. IST for i.p. administration of dioxadet, cisplatin, melphalan, mitomycin C and paclitaxel were 79 % (p < 0.001), 88 % (p < 0.001), 114 % (p < 0.001), 35 % (p < 0.002) and 45 % (p < 0.001) correspondingly compared to i.p. control group while for i.v. administration of these drugs IST were 5 % (p = 0.796), 14 % (p = 0.315), 19 % (p = 0.631), 152 % (p < 0.001) and 81 % (p = 0.023) correspondingly compared to i. v. control group. Thus, i. p. chemotherapy with alkylating agents dioxadet, cisplatin and melphalan is much more effective then their i. v. administration, while antitumor effects of i. p. and i. v. administration of paclitaxel were similar and only mitomycin C is more active at i. v. administration.

Full Text

Restricted Access

About the authors

Yekaterina Aleksandrovna Vyshinskaya

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: vea-86@mail.ru
graduate of laboratory of cancer chemoprevention and oncopharmacology

Vladimir Grigoryevich Bespalov

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: bespalov_niio@mail.ru
chief of laboratory of cancer chemoprevention and oncopharmacology

Irina Nikolayevna Vasilyeva

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: iravasilyeva@hotmail.com
graduate of laboratory of cancer chemoprevention and oncopharmacology

Aleksandr Leonidovich Semenov

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: genesem7@gmail.com
junior research fellow of cancer chemoprevention and oncopharmacology

Aleksandr Nikolayevich Stukov

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: stukov2008@yandex.ru
senior research fellow of therapeutic department

Olesya Aleksandrovna Belyayeva

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: belolesya@yandex.ru
research fellow of laboratory of cancer chemoprevention and oncopharmacology

Galina Sergeyevna Kireyeva

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: galinakireyeva@mail.ru
research fellow of laboratory of cancer chemoprevention and oncopharmacology

Eduard Dmitriyevich Gershfeld

Research-Practical Center of Specialized Kinds of Medical Care (oncologic)

Email: ed.gershfeld@gmail.com
physician oncologist of gynecologic oncologic department.

Aleksey Mikhaylovich Belyayev

N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

Email: bam281060@yandex.ru
director of N. N. Petrov Research Institute of Oncology of the Russian Ministry of Health

References

  1. Беляев А. М., Багненко С. Ф., Рухляда Н. В. Внутрибрюшинная химиотерапия злокачественных опухолей брюшной полости. СПб.: ЭЛБИ-СПб; 2007.
  2. Беляева О. А., Беспалов В. Г., Сенчик К. Ю., Коньков С. А., Стуков А. Н., Муразов Я. Г., Александров В. А. Химиоперфузионное лечение злокачественных опухолей. Медлайн экспресс. 2011; N 2-3: 58-65.
  3. Высоцкий М. М. Новое в морфогенезе и эпидемиологии рака яичников. Опухоли женской репродуктивной системы. 2012; N 2: 39-43.
  4. Горбунова В. А., ред. Диагностика и лечение рака яичников: современные аспекты: Практическое руководство. М.: Медицинское информационное агентство; 2011.
  5. Каирбаева М. Ж. Анализ результатов комбинированного лечения больных распространенным раком яичников. Сибирский онкологический журнал. 2009; N 4: 71-74.
  6. Погосянц Е. Е., Пригожина Е. Л., Еголина Н. А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ). Вопросы онкологии. 1962; 8 (11): 29-36.
  7. Стуков А. Н., Гершанович М. Л., Бланк М. А., Бланк О. А., Махнова Е. В. Противоопухолевые лекарственные средства. СПб.: NIKA; 2011.
  8. Урманчеева А. Ф., Кутушева Г. Ф., Ульрих Е. А. Опухоли яичника (клиника, диагностика и лечение). СПб.: Изд-во Н-Л; 2012.
  9. Чиссов В. И., Старинский В. В., Петров Г. В., ред. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. П. А. Герцена» Минздрава России; 2013.
  10. Cristea M., Han E., Salmon L., Morgan R. J. Practical considerations in ovarian cancer chemotherapy. Ther. Adv. Med. Oncol. 2010; 2 (3): 175-187.
  11. Hasovits C., Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin. Pharmacokinet. 2012; 51 (4): 203-224.
  12. Kemp Z., Ledermann J. Update on first-line treatment of advanced ovarian carcinoma. Int. J. Womens Health. 2013; 5: 45-51.
  13. Teo M. C. Update on the management and the role of intraperitoneal chemotherapy for ovarian cancer. Curr Opin Obstet Gynecol. 2014; 26 (1): 3-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Vyshinskaya Y.A., Bespalov V.G., Vasilyeva I.N., Semenov A.L., Stukov A.N., Belyayeva O.A., Kireyeva G.S., Gershfeld E.D., Belyayev A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 66759 от 08.08.2016 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия Эл № 77 - 6389 от 15.07.2002 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies